Your browser doesn't support javascript.
Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection.
Chen, Jun; Liu, Xiaomin; Zhang, Xinyu; Lin, Yixiao; Liu, Danping; Xun, Jingna; Wang, Zhenyan; Gu, Ling; Li, Qian; Yin, Dan; Yang, Junyang; Lu, Hongzhou.
  • Chen J; Department of Infectious Diseases and Immunology Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Liu X; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Zhang X; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Lin Y; Department of Infectious Diseases and Immunology Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Liu D; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Xun J; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Wang Z; Department of Infectious Diseases and Immunology Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Gu L; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Li Q; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Yin D; Scientific Research Center Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Yang J; Department of Infectious Diseases and Immunology Shanghai Public Health Clinical Center Fudan University Shanghai China.
  • Lu H; Wenzhou Medical University Wenzhou Zhejiang China.
Clin Transl Immunology ; 10(7): e1319, 2021.
Article in English | MEDLINE | ID: covidwho-1326764
ABSTRACT

OBJECTIVES:

This study aimed to explore the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral responses and T-cell responses in patients who have recovered from coronavirus disease 2019 (COVID-19) to understand the natural protective immune responses and to facilitate the development of vaccines.

METHODS:

We conducted a combined assessment of the changes in neutralising antibody levels and SARS-CoV-2-specific T-cell responses over time in 27 patients up to 7 months after infection.

RESULTS:

The neutralising antibody remained detectable in 96.3% of the patients at their second visit at about 7 months post-onset of symptoms. However, their humoral responses, including titres of the spike receptor-binding domain IgG and neutralising antibody, decreased significantly compared with those at first clinic visit. By contrast, the proportions of spike-specific CD4+ T cells, but not CD8+ T cells, in COVID-19 patients after recovery were persistently higher than those in healthy controls. No significant change was observed in the proportion of spike-specific CD4+ T cells in patients who had recovered from COVID-19 within 7 months.

CONCLUSION:

The SARS-CoV-2-specific T-cell immune responses persisted, while the neutralising antibodies decayed. Further studies are needed to extend the longevity of neutralising antibodies and to evaluate whether these T cells are sufficient to protect patients from reinfection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Long Covid / Vaccines Language: English Journal: Clin Transl Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Long Covid / Vaccines Language: English Journal: Clin Transl Immunology Year: 2021 Document Type: Article